Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Sep 20, 2019
Company News
China exempts 12 cancer drugs from tariffs
...since the trade war began last year. The 12 drugs include Iressa gefitinib and
Tomudex
raltitrexed
...
Read More
BioCentury
|
Mar 13, 2019
Politics & Policy
China releases timeline, priority diseases for revised reimbursement list
...Biopharmaceutical Ltd. (HKSE:1177) is also likely to benefit through inclusion of its cancer drug Saiweijian
raltitrexed
...
Read More
BioCentury
|
Apr 7, 2016
Distillery Therapeutics
Therapeutics: Thymidylate synthetase (TYMS)
...5-FU) that inhibits TYMS, to treat colorectal, gastric and breast cancers. AstraZeneca plc markets
Tomudex
raltitrexed
...
Read More
BioCentury
|
Mar 3, 2016
Targets & Mechanisms
Targeting TMP
...gene in bacteria. The bacterial enzyme is the target of several chemotherapeutics, such as
Tomudex
raltitrexed
...
Read More
BioCentury
|
Oct 18, 2010
Company News
Hospira, AstraZeneca sales and marketing update
...Hospira launched
Tomudex
raltitrexed
in Portugal, Czech Republic and Hungary for malignant pleural mesothelioma. In 2007...
Read More
BioCentury
|
Jan 5, 2009
Clinical News
AstraZeneca, Debiopharm, Hospira, Pfizer, sanofi-aventis regulatory update
...3 approved drugs: Camptosar irinotecan from Pfizer; Eloxatin oxaliplatin from sanofi-aventis and Debiopharm; and
Tomudex
raltitrexed
...
...which recommended use of Camptosar or Eloxatin as part of first-line or subsequent therapy, while
Tomudex
...
Read More
BioCentury
|
Mar 11, 2002
Clinical News
Colorectal cancer therapeutics regulatory update
...evidence of their clinical and cost effectiveness, NICE said. Also, NICE recommended that AZN's
Tomudex
raltitrexed
...
Read More
BioCentury
|
Mar 8, 2002
Politics & Policy
NICE cancer product guidance
...insufficient evidence of their clinical and cost effectiveness, NICE said. Finally, NICE recommended that
Tomudex
raltitrexed
...
Read More
BioCentury
|
May 21, 2001
Tools & Techniques
EGFr: Being 1st may not matter
...pretty impressive." Of course, AZN also has multiple products, including Zoladex , Casodex , and
Tomudex
...
Read More
Items per page:
10
1 - 9 of 9
Previous page
Next page